John Lamattina

Insider profile

Currently holds positions in Ligand Pharmaceuticals Incorporated and Larimar Therapeutics, Inc.

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return -2% 8.2% 15.1%
Success rate 55% 68% 82%
Transactions
16 44% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Ligand Pharmaceuticals Incorporated Feb. 7, 2011 -
Independent Director Larimar Therapeutics, Inc. None -
Independent Director Human Genome Sciences Inc May 7, 2008 - July 30, 2012
John Lamattina's trades of Ligand Pharmaceuticals Incorporated's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Sale
Price
2.50
Quantity 54,882
Value £137,205
Transaction date
Purchase
Price
18.58
Quantity 5,102 +10.9%
Value US$94,795
Transaction date
Purchase
Price
18.44
Quantity 338 +0.7%
Value US$6,233
Transaction date
Purchase
Price
2.50
Quantity 6,700
Value £16,750
Transaction date
Purchase
Price
2.46
Quantity 8,201
Value £20,174
Transaction date
Purchase
Price
2.32
Quantity 1,500
Value £3,480
Transaction date
Purchase
Price
2.20
Quantity 1,000
Value £2,200
Transaction date
Purchase
Price
1.63
Quantity 43,000
Value £70,090
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-12 2026-06-10
S Sale
95,755 +15.8%
326.39
US$1,407,313 		95,755 +15.8% 326.39 US$1,407,313
2026-06-12 2026-06-10
S Sale
96,573 -32.6%
333.09
US$1,634,421 		96,573 -32.6% 333.09 US$1,634,421
2026-06-12 2026-06-10
S Sale
33,546 -35.0%
140.40
US$3,102,547 		33,546 -35.0% 140.40 US$3,102,547
2026-06-12 2026-06-10
S Sale
257 -0.8%
247.22
US$63,536 		257 -0.8% 247.22 US$63,536
2026-06-10 2026-06-10
PrS Proposed sale
4,519
250.88
US$1,133,711 		4,519 250.88 US$1,133,711
2026-03-31 2026-03-06
S Sale
2,161 -6.6%
200.76
US$433,842 		2,161 -6.6% 200.76 US$433,842
2026-03-06 2026-03-06
PrS Proposed sale
2,161
200.76
US$433,842 		2,161 200.76 US$433,842
2025-11-12 2025-11-07
S Sale
2,034 -6.2%
205.45
US$417,885 		2,034 -6.2% 205.45 US$417,885
2025-11-12 2025-11-07
S Sale
2,145 -6.5%
205.45
US$440,690 		2,145 -6.5% 205.45 US$440,690
2025-11-07 2025-11-07
PrS Proposed sale
4,179
205.45
US$858,576 		4,179 205.45 US$858,576
2024-12-02 2024-11-27
S Sale
2,406 -7.5%
123.65
US$297,502 		2,406 -7.5% 123.65 US$297,502
2024-11-27 2024-11-26
PrS Proposed sale
2,406
119.19
US$286,771 		2,406 119.19 US$286,771
2024-06-27 2024-06-24
S Sale
54,882
2.50
£137,205 		54,882 2.50 £137,205
2021-11-17 2021-11-16
S Sale
4,835 -16.0%
161.86
US$782,579 		4,835 -16.0% 161.86 US$782,579
2021-05-26 2021-05-24
B Purchase
5,102 +10.9%
18.58
US$94,795 		5,102 +10.9% 18.58 US$94,795
2021-05-26 2021-05-24
B Purchase
338 +0.7%
18.44
US$6,233 		338 +0.7% 18.44 US$6,233
2020-05-21 2020-05-20
B Purchase
6,700
2.50
£16,750 		6,700 2.50 £16,750
2020-05-20 2020-05-18
B Purchase
8,201
2.46
£20,174 		8,201 2.46 £20,174
2020-05-19 2020-05-15
B Purchase
1,500
2.32
£3,480 		1,500 2.32 £3,480
2020-05-18 2020-05-14
B Purchase
1,000
2.20
£2,200 		1,000 2.20 £2,200
2018-03-15 2018-03-14
B Purchase
43,000
1.63
£70,090 		43,000 1.63 £70,090